| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HAE | Non-qualified Stock Option (Right to Buy) | Award | $0 | +9.18K | $0.00 | 9.18K | May 17, 2024 | Common Stock | 9.18K | $95.73 | Direct | F6 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023). |
| F2 | This number includes unvested restricted stock units ("RSUs") previously reported. |
| F3 | Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. |
| F4 | The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. |
| F5 | Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
| F6 | Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. |